{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "01", "@timestamp": "2020-08-01T16:16:16.000016-04:00", "@year": "2020", "@month": "08"}, "ait:date-sort": {"@day": "01", "@year": "2016", "@month": "09"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": {"xocs:funding-agency-acronym": "NIGMS", "xocs:funding-agency": "National Institute of General Medical Sciences", "xocs:funding-id": "U54GM104942", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/100000057", "xocs:funding-agency-country": "http://sws.geonames.org/6252001"}, "xocs:funding-addon-generated-timestamp": "2024-02-02T01:22:51.149067Z", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "United States", "@afid": "60015277", "@country": "usa", "city": "Philadelphia", "organization": {"$": "Thomas Jefferson University"}, "affiliation-id": {"@afid": "60015277"}, "state": "PA"}, "author": [{"ce:given-name": "Kathleen", "preferred-name": {"ce:given-name": "Kathleen", "ce:initials": "K.", "ce:surname": "Squires", "ce:indexed-name": "Squires K."}, "@seq": "1", "ce:initials": "K.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Squires", "@auid": "35394567100", "ce:indexed-name": "Squires K."}]}, {"affiliation": {"country": "Uganda", "@afid": "60071691", "@country": "uga", "city": "Kampala", "organization": [{"$": "Joint Clinical Research Centre"}, {"$": "Clinical Research"}], "affiliation-id": {"@afid": "60071691"}}, "author": [{"ce:given-name": "Cissy", "preferred-name": {"ce:given-name": "Cissy", "ce:initials": "C.", "ce:surname": "Kityo", "ce:indexed-name": "Kityo C."}, "@seq": "2", "ce:initials": "C.", "@_fa": "true", "@type": "auth", "ce:degrees": "MSc", "ce:surname": "Kityo", "@auid": "6602918610", "ce:indexed-name": "Kityo C."}]}, {"affiliation": {"country": "United States", "@afid": "60021143", "@country": "usa", "city": "Morgantown", "organization": {"$": "West Virginia University"}, "affiliation-id": {"@afid": "60021143"}, "state": "WV"}, "author": [{"ce:given-name": "Sally", "preferred-name": {"ce:given-name": "Sally", "ce:initials": "S.", "ce:surname": "Hodder", "ce:indexed-name": "Hodder S."}, "@seq": "3", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Hodder", "@auid": "35558534100", "ce:indexed-name": "Hodder S."}]}, {"affiliation": {"country": "United Kingdom", "@afid": "60032819", "@country": "gbr", "city": "London", "organization": [{"$": "Royal Free Hospital"}, {"$": "Hampstead"}], "affiliation-id": {"@afid": "60032819"}}, "author": [{"ce:given-name": "Margaret", "preferred-name": {"ce:given-name": "Margaret", "ce:initials": "M.", "ce:surname": "Johnson", "ce:indexed-name": "Johnson M."}, "@seq": "4", "ce:initials": "M.", "@_fa": "true", "@type": "auth", "ce:degrees": "FRCP", "ce:surname": "Johnson", "@auid": "56339842100", "ce:indexed-name": "Johnson M."}]}, {"affiliation": {"country": "Russian Federation", "@afid": "100865118", "@country": "rus", "city": "St Petersburg", "organization": {"$": "Regional Clinic in Infectious Hospital"}, "affiliation-id": {"@afid": "100865118"}}, "author": [{"ce:given-name": "Evgeny", "preferred-name": {"ce:given-name": "Evgeny", "ce:initials": "E.", "ce:surname": "Voronin", "ce:indexed-name": "Voronin E."}, "@seq": "5", "ce:initials": "E.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Voronin", "@auid": "7005899830", "ce:indexed-name": "Voronin E."}]}, {"affiliation": {"country": "United States", "@afid": "101795564", "@country": "usa", "city": "Savannah", "organization": {"$": "Chatham County Health Department"}, "affiliation-id": {"@afid": "101795564"}, "state": "GA"}, "author": [{"ce:given-name": "Debbie", "preferred-name": {"ce:given-name": "Debbie", "ce:initials": "D.", "ce:surname": "Hagins", "ce:indexed-name": "Hagins D."}, "@seq": "6", "ce:initials": "D.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Hagins", "@auid": "36522862600", "ce:indexed-name": "Hagins D."}]}, {"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "HIV-NAT"}, {"$": "Thai Red Cross AIDS Research Center and Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": [{"@afid": "60028190"}, {"@afid": "60031780"}, {"@afid": "60016965"}]}, "author": [{"ce:given-name": "Anchalee", "preferred-name": {"ce:given-name": "Anchalee", "ce:initials": "A.", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, "@seq": "7", "ce:initials": "A.", "@date-locked": "2018-07-27T21:17:03.882", "@_fa": "true", "@type": "auth", "ce:surname": "Avihingsanon", "@auid": "57196347321", "ce:indexed-name": "Avihingsanon A."}]}, {"affiliation": {"country": "Dominican Republic", "@afid": "116701788", "@country": "dom", "city": "Santo Domingo", "organization": {"$": "Zona Universitaria/IDEV"}, "affiliation-id": {"@afid": "116701788"}}, "author": [{"ce:given-name": "Ellen", "preferred-name": {"ce:given-name": "Ellen", "ce:initials": "E.", "ce:surname": "Koenig", "ce:indexed-name": "Koenig E."}, "@seq": "8", "ce:initials": "E.", "@_fa": "true", "@type": "auth", "ce:surname": "Koenig", "@auid": "7005320371", "ce:indexed-name": "Koenig E."}]}, {"affiliation": {"country": "United States", "@afid": "60002909", "@country": "usa", "city": "Foster City", "organization": {"$": "Gilead Sciences"}, "affiliation-id": {"@afid": "60002909"}, "state": "CA"}, "author": [{"ce:given-name": "Shuping", "preferred-name": {"ce:given-name": "Shuping", "ce:initials": "S.", "ce:surname": "Jiang", "ce:indexed-name": "Jiang S."}, "@seq": "9", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:degrees": "PhD", "ce:surname": "Jiang", "@auid": "57189385625", "ce:indexed-name": "Jiang S."}, {"ce:given-name": "Kirsten", "preferred-name": {"ce:given-name": "Kirsten", "ce:initials": "K.", "ce:surname": "White", "ce:indexed-name": "White K."}, "@seq": "10", "ce:initials": "K.", "@_fa": "true", "@type": "auth", "ce:degrees": "PhD", "ce:surname": "White", "@auid": "7402810067", "ce:indexed-name": "White K."}, {"ce:given-name": "Andrew", "preferred-name": {"ce:given-name": "Andrew", "ce:initials": "A.", "ce:surname": "Cheng", "ce:indexed-name": "Cheng A."}, "@seq": "11", "ce:initials": "A.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Cheng", "@auid": "7402075263", "ce:indexed-name": "Cheng A."}, {"ce:given-name": "Javier", "preferred-name": {"ce:given-name": "Javier", "ce:initials": "J.", "ce:surname": "Szwarcberg", "ce:indexed-name": "Szwarcberg J."}, "@seq": "12", "ce:initials": "J.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Szwarcberg", "@auid": "6602738587", "ce:indexed-name": "Szwarcberg J."}, {"ce:given-name": "Huyen", "preferred-name": {"ce:given-name": "Huyen", "ce:initials": "H.", "ce:surname": "Cao", "ce:indexed-name": "Cao H."}, "@seq": "13", "ce:initials": "H.", "@_fa": "true", "@type": "auth", "ce:degrees": "MD", "ce:surname": "Cao", "@auid": "56471119200", "ce:indexed-name": "Cao H."}]}], "citation-title": "Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study", "abstracts": "\u00a9 2016 Elsevier LtdBackground Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not contain sex-specific treatment. We aimed to assess the safety and efficacy of the single tablet integrase inhibitor regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted protease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate. Methods In this international, randomised, controlled, double-blind, phase 3 study (Women AntiretroViral Efficacy and Safety study [WAVES]), we recruited treatment-naive HIV-infected women with an estimated creatinine clearance of 70 mL/min or higher from 80 centres in 11 countries. Women were randomly assigned (1:1) to receive elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regimen) or ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based regimen); regimens were masked with matching placebos. Randomisation was done by a computer-generated allocation sequence (block size four) and was stratified by HIV-1 RNA viral load and race. Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary efficacy and safety analyses. The main outcome was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by US Food and Drug Administration snapshot algorithm (prespecified non-inferiority margin of 12%). This study is registered with ClinicalTrials.gov, number NCT01705574. Findings Between Nov 28, 2012, and March 12, 2014, 575 women were enrolled. 289 were randomly assigned to receive the integrase inhibitor regimen and 286 to receive the protease inhibitor based regimen. 252 (87%) women in the integrase inhibitor group had plasma HIV-1 RNA less than 50 copies per mL at week 48 compared with 231 (81%) women in the protease inhibitor group (adjusted difference 6\u00b75%; 95% CI 0\u00b74\u201312\u00b76). No participant had virological failure with resistance in the integrase inhibitor group compared with three participants ([1%]; all Met184Val/Ile) in the protease inhibitor group. 19 women in the protease inhibitor group discontinued because of adverse events compared with five in the integrase inhibitor group. Interpretation WAVES shows that clinical trials of ART regimens in global and diverse populations of treatment-naive women are possible. The findings support guidelines recommending integrase inhibitor based regimens in first-line antiretroviral therapy. Funding Gilead Sciences.", "correspondence": {"affiliation": {"country": "United States", "postal-code": "94404", "@country": "usa", "city": "Foster City", "organization": [{"$": "Gilead Sciences"}, {"$": "HIV Clinical Research"}], "state": "CA"}, "person": {"ce:given-name": "Huyen", "ce:initials": "H.", "ce:degrees": "MD", "ce:surname": "Cao", "ce:indexed-name": "Cao H."}}, "citation-info": {"citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"sourcetitle-abbrev": "Lancet HIV", "website": {"ce:e-address": {"$": "http://www.journals.elsevier.com/the-lancet-hiv/", "@type": "email"}}, "@country": "gbr", "translated-sourcetitle": {"@xml:lang": "eng"}, "issn": {"$": "23523018", "@type": "electronic"}, "volisspag": {"voliss": {"@volume": "3", "@issue": "9"}, "pagerange": {"@first": "e410", "@last": "e420"}}, "@type": "j", "publicationyear": {"@first": "2016"}, "publisher": {"publishername": "Elsevier Ltd"}, "sourcetitle": "The Lancet HIV", "@srcid": "21100369870", "publicationdate": {"month": "09", "year": "2016", "date-text": {"@xfab-added": "true", "$": "1 September 2016"}, "day": "01"}}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "29", "classification-description": "Clinical and Experimental Biochemistry"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "38", "classification-description": "Adverse Reactions Titles"}, {"classification-code": "4", "classification-description": "Microbiology: Bacteriology, Mycology, Parasitology and Virology"}]}, {"@type": "ASJC", "classification": [{"$": "2713"}, {"$": "2403"}, {"$": "2725"}, {"$": "2406"}]}, {"@type": "SUBJABBR", "classification": [{"$": "MEDI"}, {"$": "IMMU"}]}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": [{"$": "9000-90-2"}, {"$": "9000-92-4"}, {"$": "9001-19-8"}], "enzyme-commission-number": "EC 3.2.1.1", "chemical-name": "amylase"}, {"cas-registry-number": "198904-31-3", "chemical-name": "atazanavir"}, {"cas-registry-number": [{"$": "19230-81-0"}, {"$": "60-27-5"}], "chemical-name": "creatinine"}, {"cas-registry-number": [{"$": "137530-41-7"}, {"$": "143491-54-7"}, {"$": "143491-57-0"}], "chemical-name": "emtricitabine"}, {"cas-registry-number": "136461-80-8", "chemical-name": "osteocalcin"}, {"cas-registry-number": [{"$": "39287-99-5"}, {"$": "68651-94-5"}], "enzyme-commission-number": "EC 3.4.24.14", "chemical-name": "procollagen n proteinase"}, {"cas-registry-number": "155213-67-5", "chemical-name": "ritonavir"}, {"cas-registry-number": "202138-50-9", "chemical-name": "tenofovir disoproxil"}, {"cas-registry-number": "1004316-88-4", "chemical-name": "cobicistat"}, {"cas-registry-number": "697761-98-1", "chemical-name": "elvitegravir"}, {"cas-registry-number": [{"$": "147127-19-3"}, {"$": "147127-20-6"}], "chemical-name": "tenofovir"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Atazanavir Sulfate"}, {"chemical-name": "Cobicistat"}, {"chemical-name": "Emtricitabine"}, {"chemical-name": "HIV Integrase Inhibitors"}, {"chemical-name": "HIV Protease Inhibitors"}, {"chemical-name": "JTK 303"}, {"chemical-name": "Quinolones"}, {"chemical-name": "Ritonavir"}, {"chemical-name": "RNA, Viral"}, {"chemical-name": "Tenofovir"}]}]}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "EMBASE"}, {"$": "MEDL"}, {"$": "NURSNG"}, {"$": "REAXYSCAR"}, {"$": "SNEMB"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "21", "@timestamp": "BST 16:59:12", "@year": "2017", "@month": "07"}}, "itemidlist": {"itemid": [{"$": "610538418", "@idtype": "PUI"}, {"$": "650916715", "@idtype": "CAR-ID"}, {"$": "20160402090", "@idtype": "EMBASE"}, {"$": "27562742", "@idtype": "MEDL"}, {"$": "2016187989", "@idtype": "NURSNG"}, {"$": "20161260664", "@idtype": "REAXYSCAR"}, {"$": "2016059418", "@idtype": "SNEMB"}, {"$": "84969972261", "@idtype": "SCP"}, {"$": "84969972261", "@idtype": "SGR"}, {"$": "617395365", "@idtype": "PUIsecondary"}], "ce:pii": "S2352301816300169", "ce:doi": "10.1016/S2352-3018(16)30016-9"}}, "tail": {"bibliography": {"@refcount": "33", "reference": [{"ref-fulltext": "1 Joint United Nations Programme on HIV/AIDS (UNAIDS). Global report: UNAIDS report on the global AIDS epidemic 2013. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf (accessed June 18, 2015).", "@id": "1", "ref-info": {"ref-website": {"ce:e-address": {"$": "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf", "@type": "email"}}, "ref-title": {"ref-titletext": "Global report: UNAIDS report on the global AIDS epidemic 2013"}, "refd-itemidlist": {"itemid": {"$": "84925440919", "@idtype": "SGR"}}, "ref-text": "(accessed June 18, 2015).", "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "Joint United Nations Programme on HIV/AIDS (UNAIDS)", "ce:indexed-name": "Joint United Nations Programme on HIV/AIDS (UNAIDS)"}}}}, {"ref-fulltext": "2 Sherman, LA, Temple, R, Merkatz, RB, Women in clinical trials: an FDA perspective. Science 26 (1995), 793\u2013795.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "1995"}, "ref-title": {"ref-titletext": "Women in clinical trials: an FDA perspective"}, "refd-itemidlist": {"itemid": {"$": "0029155843", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "26"}, "pagerange": {"@first": "793", "@last": "795"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.A.", "@_fa": "true", "ce:surname": "Sherman", "ce:indexed-name": "Sherman L.A."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Temple", "ce:indexed-name": "Temple R."}, {"@seq": "3", "ce:initials": "R.B.", "@_fa": "true", "ce:surname": "Merkatz", "ce:indexed-name": "Merkatz R.B."}]}, "ref-sourcetitle": "Science"}}, {"ref-fulltext": "3 Bennett, JC, Inclusion of women in clinical trials\u2013policies for population subgroups. N Engl J Med 329 (1993), 288\u2013292.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "1993"}, "ref-title": {"ref-titletext": "Inclusion of women in clinical trials\u2013policies for population subgroups"}, "refd-itemidlist": {"itemid": {"$": "0027198951", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "329"}, "pagerange": {"@first": "288", "@last": "292"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Bennett", "ce:indexed-name": "Bennett J.C."}]}, "ref-sourcetitle": "N Engl J Med"}}, {"ref-fulltext": "4 Soon, GG, Min, M, Struble, KA, et al. Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008). AIDS Patient Care STDS 26 (2012), 444\u2013453.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008)"}, "refd-itemidlist": {"itemid": {"$": "84864719749", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "26"}, "pagerange": {"@first": "444", "@last": "453"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.G.", "@_fa": "true", "ce:surname": "Soon", "ce:indexed-name": "Soon G.G."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Min", "ce:indexed-name": "Min M."}, {"@seq": "3", "ce:initials": "K.A.", "@_fa": "true", "ce:surname": "Struble", "ce:indexed-name": "Struble K.A."}], "et-al": null}, "ref-sourcetitle": "AIDS Patient Care STDS"}}, {"ref-fulltext": "5 Monforte, A, Anderson, J, Olczak, A, What do we know about antiretroviral treatment of HIV in women?. Antivir Ther 18 (2013), 27\u201334.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "What do we know about antiretroviral treatment of HIV in women?"}, "refd-itemidlist": {"itemid": {"$": "84879614774", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "18"}, "pagerange": {"@first": "27", "@last": "34"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Monforte", "ce:indexed-name": "Monforte A."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Anderson", "ce:indexed-name": "Anderson J."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Olczak", "ce:indexed-name": "Olczak A."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "6 Hodder, S, Arasteh, K, De Wet, J, et al. Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE. HIV Med 13 (2012), 406\u2013415.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Effect of gender and race on the week 48 findings in treatment-naive, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE"}, "refd-itemidlist": {"itemid": {"$": "84863190048", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "13"}, "pagerange": {"@first": "406", "@last": "415"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Hodder", "ce:indexed-name": "Hodder S."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Arasteh", "ce:indexed-name": "Arasteh K."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "De Wet", "ce:indexed-name": "De Wet J."}], "et-al": null}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "7 Umeh, OC, Currier, JS, Sex differences in pharmacokinetics and toxicity of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2 (2006), 273\u2013283.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Sex differences in pharmacokinetics and toxicity of antiretroviral therapy"}, "refd-itemidlist": {"itemid": {"$": "33847761503", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "2"}, "pagerange": {"@first": "273", "@last": "283"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "O.C.", "@_fa": "true", "ce:surname": "Umeh", "ce:indexed-name": "Umeh O.C."}, {"@seq": "2", "ce:initials": "J.S.", "@_fa": "true", "ce:surname": "Currier", "ce:indexed-name": "Currier J.S."}]}, "ref-sourcetitle": "Expert Opin Drug Metab Toxicol"}}, {"ref-fulltext": "8 Currier, J, Averitt Bridge, D, Hagins, D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med 153 (2010), 349\u2013357.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial"}, "refd-itemidlist": {"itemid": {"$": "77957354649", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "153"}, "pagerange": {"@first": "349", "@last": "357"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Currier", "ce:indexed-name": "Currier J."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Averitt Bridge", "ce:indexed-name": "Averitt Bridge D."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Hagins", "ce:indexed-name": "Hagins D."}], "et-al": null}, "ref-sourcetitle": "Ann Intern Med"}}, {"ref-fulltext": "9 d'Arminio Monforte, A, Gonzalez, L, Haberl, A, Sherr, L, Ssanyu-Sseruma, W, Walmsley, SL, Better mind the gap: addressing the shortage of HIV-positive women in clinical trials. AIDS 24 (2010), 1091\u20131094.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Better mind the gap: addressing the shortage of HIV-positive women in clinical trials"}, "refd-itemidlist": {"itemid": {"$": "77951880542", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24"}, "pagerange": {"@first": "1091", "@last": "1094"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "d'Arminio Monforte", "ce:indexed-name": "d'Arminio Monforte A."}, {"@seq": "2", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Gonzalez", "ce:indexed-name": "Gonzalez L."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Haberl", "ce:indexed-name": "Haberl A."}, {"@seq": "4", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Sherr", "ce:indexed-name": "Sherr L."}, {"@seq": "5", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Ssanyu-Sseruma", "ce:indexed-name": "Ssanyu-Sseruma W."}, {"@seq": "6", "ce:initials": "S.L.", "@_fa": "true", "ce:surname": "Walmsley", "ce:indexed-name": "Walmsley S.L."}]}, "ref-sourcetitle": "AIDS"}}, {"ref-fulltext": "10 EACS. European AIDS Clinical Society Guidelines. http://www.eacsociety.org/files/guidelines-7.1-english.pdf, November, 2014 (accessed June 18, 2015).", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-website": {"ce:e-address": {"$": "http://www.eacsociety.org/files/guidelines-7.1-english.pdf", "@type": "email"}}, "ref-title": {"ref-titletext": "European AIDS Clinical Society Guidelines"}, "refd-itemidlist": {"itemid": {"$": "84920170893", "@idtype": "SGR"}}, "ref-text": "(accessed June 18, 2015).", "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "EACS", "ce:indexed-name": "EACS"}}}}, {"ref-fulltext": "11 DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf (accessed June 18, 2015.", "@id": "11", "ref-info": {"ref-website": {"ce:e-address": {"$": "https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf", "@type": "email"}}, "ref-title": {"ref-titletext": "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents"}, "refd-itemidlist": {"itemid": {"$": "84871869890", "@idtype": "SGR"}}, "ref-text": "(accessed June 18, 2015.", "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents", "ce:indexed-name": "DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents"}}}}, {"ref-fulltext": "12 WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/hiv/pub/guidelines/arv2013/en/, 2013 (accessed June 19, 2015).", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-website": {"ce:e-address": {"$": "http://www.who.int/hiv/pub/guidelines/arv2013/en/", "@type": "email"}}, "ref-title": {"ref-titletext": "Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection"}, "refd-itemidlist": {"itemid": {"$": "84882279538", "@idtype": "SGR"}}, "ref-text": "(accessed June 19, 2015).", "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "WHO", "ce:indexed-name": "WHO"}}}}, {"ref-fulltext": "13 Johnson, M, Walmsley, S, Haberl, A, A systematic review of the use of atazanavir in women infected with HIV-1. Antivir Ther 19 (2014), 293\u2013307.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "A systematic review of the use of atazanavir in women infected with HIV-1"}, "refd-itemidlist": {"itemid": {"$": "84902655479", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19"}, "pagerange": {"@first": "293", "@last": "307"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Johnson", "ce:indexed-name": "Johnson M."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Walmsley", "ce:indexed-name": "Walmsley S."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Haberl", "ce:indexed-name": "Haberl A."}]}, "ref-sourcetitle": "Antivir Ther"}}, {"ref-fulltext": "14 Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf, March 28, 2014 (accessed June 18, 2016).", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-website": {"ce:e-address": {"$": "https://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf", "@type": "email"}}, "ref-title": {"ref-titletext": "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States"}, "refd-itemidlist": {"itemid": {"$": "78349284496", "@idtype": "SGR"}}, "ref-text": "(accessed June 18, 2016). March 28", "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission", "ce:indexed-name": "Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission"}}}}, {"ref-fulltext": "15 US Department of Health and Human Services. Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm355239.htm, 2013 (accessed May 26, 2016).", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-website": {"ce:e-address": {"$": "http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm355239.htm", "@type": "email"}}, "ref-title": {"ref-titletext": "Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment"}, "refd-itemidlist": {"itemid": {"$": "84904257558", "@idtype": "SGR"}}, "ref-text": "(accessed May 26, 2016).", "ref-authors": {"collaboration": {"@seq": "1", "ce:text": "US Department of Health and Human Services", "ce:indexed-name": "US Department of Health and Human Services"}}}}, {"ref-fulltext": "16 Firnhaber, C, Smeaton, LM, Grinsztejn, B, et al. Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial. HIV Clin Trials 16 (2015), 89\u201399.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial"}, "refd-itemidlist": {"itemid": {"$": "84948424808", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16"}, "pagerange": {"@first": "89", "@last": "99"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Firnhaber", "ce:indexed-name": "Firnhaber C."}, {"@seq": "2", "ce:initials": "L.M.", "@_fa": "true", "ce:surname": "Smeaton", "ce:indexed-name": "Smeaton L.M."}, {"@seq": "3", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Grinsztejn", "ce:indexed-name": "Grinsztejn B."}], "et-al": null}, "ref-sourcetitle": "HIV Clin Trials"}}, {"ref-fulltext": "17 Campbell, TB, Smeaton, LM, Kumarasamy, N, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med, 9, 2012, e1001290.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings"}, "refd-itemidlist": {"itemid": {"$": "84865566725", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9"}, "pagerange": {"@first": "e1001290"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.B.", "@_fa": "true", "ce:surname": "Campbell", "ce:indexed-name": "Campbell T.B."}, {"@seq": "2", "ce:initials": "L.M.", "@_fa": "true", "ce:surname": "Smeaton", "ce:indexed-name": "Smeaton L.M."}, {"@seq": "3", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Kumarasamy", "ce:indexed-name": "Kumarasamy N."}], "et-al": null}, "ref-sourcetitle": "PLoS Med"}}, {"ref-fulltext": "18 Smith, KY, Tierney, C, Mollan, K, et al. Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine. Clin Infect Dis 58 (2014), 555\u2013563.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine"}, "refd-itemidlist": {"itemid": {"$": "84893309602", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "58"}, "pagerange": {"@first": "555", "@last": "563"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.Y.", "@_fa": "true", "ce:surname": "Smith", "ce:indexed-name": "Smith K.Y."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Tierney", "ce:indexed-name": "Tierney C."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Mollan", "ce:indexed-name": "Mollan K."}], "et-al": null}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "19 Squires, KE, Johnson, M, Yang, R, et al. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother 66 (2011), 363\u2013370.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study"}, "refd-itemidlist": {"itemid": {"$": "78651467285", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "66"}, "pagerange": {"@first": "363", "@last": "370"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.E.", "@_fa": "true", "ce:surname": "Squires", "ce:indexed-name": "Squires K.E."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Johnson", "ce:indexed-name": "Johnson M."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Yang", "ce:indexed-name": "Yang R."}], "et-al": null}, "ref-sourcetitle": "J Antimicrob Chemother"}}, {"ref-fulltext": "20 Zulliger, R, Barrington, C, Donastorg, Y, Perez, M, Kerrigan, D, High drop-off along the HIV care continuum and ART interruption among female sex workers in the Dominican Republic. J Acquir Immune Defic Syndr 69 (2015), 216\u2013222.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "High drop-off along the HIV care continuum and ART interruption among female sex workers in the Dominican Republic"}, "refd-itemidlist": {"itemid": {"$": "84929906182", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "69"}, "pagerange": {"@first": "216", "@last": "222"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Zulliger", "ce:indexed-name": "Zulliger R."}, {"@seq": "2", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Barrington", "ce:indexed-name": "Barrington C."}, {"@seq": "3", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Donastorg", "ce:indexed-name": "Donastorg Y."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Perez", "ce:indexed-name": "Perez M."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Kerrigan", "ce:indexed-name": "Kerrigan D."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "21 Cuzin, L, Flandre, P, Pugliese, P, et al. Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort. HIV Clin Trials 9 (2008), 147\u2013151.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Atazanavir in patients with persistent viral replication despite HAART: results from the French prospective NADIS cohort"}, "refd-itemidlist": {"itemid": {"$": "45949095398", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9"}, "pagerange": {"@first": "147", "@last": "151"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Cuzin", "ce:indexed-name": "Cuzin L."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Flandre", "ce:indexed-name": "Flandre P."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Pugliese", "ce:indexed-name": "Pugliese P."}], "et-al": null}, "ref-sourcetitle": "HIV Clin Trials"}}, {"ref-fulltext": "22 Tedaldi, EM, Absalon, J, Thomas, AJ, Shlay, JC, van den Berg-Wolf, M, Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr 47 (2008), 441\u2013448.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2008"}, "ref-title": {"ref-titletext": "Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: results of CPCRA 058 (FIRST Study)"}, "refd-itemidlist": {"itemid": {"$": "40549097017", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "47"}, "pagerange": {"@first": "441", "@last": "448"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.M.", "@_fa": "true", "ce:surname": "Tedaldi", "ce:indexed-name": "Tedaldi E.M."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Absalon", "ce:indexed-name": "Absalon J."}, {"@seq": "3", "ce:initials": "A.J.", "@_fa": "true", "ce:surname": "Thomas", "ce:indexed-name": "Thomas A.J."}, {"@seq": "4", "ce:initials": "J.C.", "@_fa": "true", "ce:surname": "Shlay", "ce:indexed-name": "Shlay J.C."}, {"@seq": "5", "ce:initials": "M.", "@_fa": "true", "ce:surname": "van den Berg-Wolf", "ce:indexed-name": "van den Berg-Wolf M."}]}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "23 Bersoff-Matcha, SJ, Miller, WC, Aberg, JA, et al. Sex differences in nevirapine rash. Clin Infect Dis 32 (2001), 124\u2013129.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Sex differences in nevirapine rash"}, "refd-itemidlist": {"itemid": {"$": "0035134608", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32"}, "pagerange": {"@first": "124", "@last": "129"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Bersoff-Matcha", "ce:indexed-name": "Bersoff-Matcha S.J."}, {"@seq": "2", "ce:initials": "W.C.", "@_fa": "true", "ce:surname": "Miller", "ce:indexed-name": "Miller W.C."}, {"@seq": "3", "ce:initials": "J.A.", "@_fa": "true", "ce:surname": "Aberg", "ce:indexed-name": "Aberg J.A."}], "et-al": null}, "ref-sourcetitle": "Clin Infect Dis"}}, {"ref-fulltext": "24 Mocroft, A, Kirk, O, Reiss, P, et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 24 (2010), 1667\u20131678.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients"}, "refd-itemidlist": {"itemid": {"$": "77954349373", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "24"}, "pagerange": {"@first": "1667", "@last": "1678"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Mocroft", "ce:indexed-name": "Mocroft A."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Kirk", "ce:indexed-name": "Kirk O."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Reiss", "ce:indexed-name": "Reiss P."}], "et-al": null}, "ref-sourcetitle": "AIDS"}}, {"ref-fulltext": "25 Morlat, P, Vivot, A, Vandenhende, MA, et al. Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004\u20132012. PLoS One, 8, 2013, e66223.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004\u20132012"}, "refd-itemidlist": {"itemid": {"$": "84878936689", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8"}, "pagerange": {"@first": "e66223"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Morlat", "ce:indexed-name": "Morlat P."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Vivot", "ce:indexed-name": "Vivot A."}, {"@seq": "3", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Vandenhende", "ce:indexed-name": "Vandenhende M.A."}], "et-al": null}, "ref-sourcetitle": "PLoS One"}}, {"ref-fulltext": "26 Winston, J, Chonchol, M, Gallant, J, et al. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naive HIV-1 patients: meta-analysis of randomized clinical studies. HIV Clin Trials 15 (2014), 231\u2013245.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naive HIV-1 patients: meta-analysis of randomized clinical studies"}, "refd-itemidlist": {"itemid": {"$": "84916221171", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15"}, "pagerange": {"@first": "231", "@last": "245"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Winston", "ce:indexed-name": "Winston J."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Chonchol", "ce:indexed-name": "Chonchol M."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Gallant", "ce:indexed-name": "Gallant J."}], "et-al": null}, "ref-sourcetitle": "HIV Clin Trials"}}, {"ref-fulltext": "27 DeJesus, E, Rockstroh, JK, Henry, K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379 (2012), 2429\u20132438.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2012"}, "ref-title": {"ref-titletext": "Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial"}, "refd-itemidlist": {"itemid": {"$": "84862843404", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "379"}, "pagerange": {"@first": "2429", "@last": "2438"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "DeJesus", "ce:indexed-name": "DeJesus E."}, {"@seq": "2", "ce:initials": "J.K.", "@_fa": "true", "ce:surname": "Rockstroh", "ce:indexed-name": "Rockstroh J.K."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Henry", "ce:indexed-name": "Henry K."}], "et-al": null}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "28 Rockstroh, JK, DeJesus, E, Henry, K, et al. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 62 (2013), 483\u2013486.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results"}, "refd-itemidlist": {"itemid": {"$": "84876409173", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62"}, "pagerange": {"@first": "483", "@last": "486"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.K.", "@_fa": "true", "ce:surname": "Rockstroh", "ce:indexed-name": "Rockstroh J.K."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "DeJesus", "ce:indexed-name": "DeJesus E."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Henry", "ce:indexed-name": "Henry K."}], "et-al": null}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "29 Moore, AL, Kirk, O, Johnson, AM, et al. Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited. J Acquir Immune Defic Syndr 32 (2003), 452\u2013461.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited"}, "refd-itemidlist": {"itemid": {"$": "0037378569", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32"}, "pagerange": {"@first": "452", "@last": "461"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.L.", "@_fa": "true", "ce:surname": "Moore", "ce:indexed-name": "Moore A.L."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Kirk", "ce:indexed-name": "Kirk O."}, {"@seq": "3", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Johnson", "ce:indexed-name": "Johnson A.M."}], "et-al": null}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}, {"ref-fulltext": "30 Kumar, PN, Rodriguez-French, A, Thompson, MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 7 (2006), 85\u201398.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity"}, "refd-itemidlist": {"itemid": {"$": "33645988818", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "85", "@last": "98"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.N.", "@_fa": "true", "ce:surname": "Kumar", "ce:indexed-name": "Kumar P.N."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Rodriguez-French", "ce:indexed-name": "Rodriguez-French A."}, {"@seq": "3", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Thompson", "ce:indexed-name": "Thompson M.A."}], "et-al": null}, "ref-sourcetitle": "HIV Med"}}, {"ref-fulltext": "31 Squires, KE, Hodder, SL, Feinberg, J, et al. Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDs 25 (2011), 279\u2013285.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "ref-title": {"ref-titletext": "Health needs of HIV-infected women in the United States: insights from the women living positive survey"}, "refd-itemidlist": {"itemid": {"$": "79955780208", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "25"}, "pagerange": {"@first": "279", "@last": "285"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.E.", "@_fa": "true", "ce:surname": "Squires", "ce:indexed-name": "Squires K.E."}, {"@seq": "2", "ce:initials": "S.L.", "@_fa": "true", "ce:surname": "Hodder", "ce:indexed-name": "Hodder S.L."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Feinberg", "ce:indexed-name": "Feinberg J."}], "et-al": null}, "ref-sourcetitle": "AIDS Patient Care STDs"}}, {"ref-fulltext": "32 Blair, JM, Fagan, JL, Frazier, EL, et al. Behavioral and clinical characteristics of persons receiving medical care for HIV infection\u2014Medical Monitoring Project, United States, 2009. MMWR Surveill Summ 63 (2014), 1\u201322.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Behavioral and clinical characteristics of persons receiving medical care for HIV infection\u2014Medical Monitoring Project, United States, 2009"}, "refd-itemidlist": {"itemid": {"$": "84903474657", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "63"}, "pagerange": {"@first": "1", "@last": "22"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Blair", "ce:indexed-name": "Blair J.M."}, {"@seq": "2", "ce:initials": "J.L.", "@_fa": "true", "ce:surname": "Fagan", "ce:indexed-name": "Fagan J.L."}, {"@seq": "3", "ce:initials": "E.L.", "@_fa": "true", "ce:surname": "Frazier", "ce:indexed-name": "Frazier E.L."}], "et-al": null}, "ref-sourcetitle": "MMWR Surveill Summ"}}, {"ref-fulltext": "33 McFall, AM, Dowdy, DW, Zelaya, CE, et al. Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity. J Acquir Immune Defic Syndr 64 (2013), 289\u2013298.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Understanding the disparity: predictors of virologic failure in women using highly active antiretroviral therapy vary by race and/or ethnicity"}, "refd-itemidlist": {"itemid": {"$": "84886407736", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "64"}, "pagerange": {"@first": "289", "@last": "298"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "McFall", "ce:indexed-name": "McFall A.M."}, {"@seq": "2", "ce:initials": "D.W.", "@_fa": "true", "ce:surname": "Dowdy", "ce:indexed-name": "Dowdy D.W."}, {"@seq": "3", "ce:initials": "C.E.", "@_fa": "true", "ce:surname": "Zelaya", "ce:indexed-name": "Zelaya C.E."}], "et-al": null}, "ref-sourcetitle": "J Acquir Immune Defic Syndr"}}]}}}}, "affiliation": [{"affiliation-city": "Kampala", "@id": "60071691", "affilname": "Joint Clinical Research Center Uganda", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691", "affiliation-country": "Uganda"}, {"affiliation-city": "London", "@id": "60032819", "affilname": "The Royal Free Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032819", "affiliation-country": "United Kingdom"}, {"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, {"affiliation-city": "Morgantown", "@id": "60021143", "affilname": "West Virginia University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021143", "affiliation-country": "United States"}, {"affiliation-city": "Philadelphia", "@id": "60015277", "affilname": "Thomas Jefferson University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015277", "affiliation-country": "United States"}, {"affiliation-city": "Foster City", "@id": "60002909", "affilname": "Gilead Sciences Incorporated", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909", "affiliation-country": "United States"}, {"affiliation-city": "Santo Domingo", "@id": "116701788", "affilname": "Zona Universitaria/IDEV", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/116701788", "affiliation-country": "Dominican Republic"}, {"affiliation-city": "Savannah", "@id": "101795564", "affilname": "Chatham County Health Department", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101795564", "affiliation-country": "United States"}, {"affiliation-city": "Saint Petersburg (ex Leningrad)", "@id": "100865118", "affilname": "Regional Clinic in Infectious Hospital", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100865118", "affiliation-country": "Russian Federation"}], "coredata": {"srctype": "j", "eid": "2-s2.0-84969972261", "dc:description": "Background Women are under-represented in HIV antiretroviral therapy (ART) studies. Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not contain sex-specific treatment. We aimed to assess the safety and efficacy of the single tablet integrase inhibitor regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate compared with a boosted protease inhibitor regimen of ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate. Methods In this international, randomised, controlled, double-blind, phase 3 study (Women AntiretroViral Efficacy and Safety study [WAVES]), we recruited treatment-naive HIV-infected women with an estimated creatinine clearance of 70 mL/min or higher from 80 centres in 11 countries. Women were randomly assigned (1:1) to receive elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (integrase inhibitor regimen) or ritonavir-boosted atazanavir with emtricitabine and tenofovir disoproxil fumarate (protease inhibitor based regimen); regimens were masked with matching placebos. Randomisation was done by a computer-generated allocation sequence (block size four) and was stratified by HIV-1 RNA viral load and race. Investigators, patients, study staff, and those assessing outcomes were masked to treatment group. All participants who received one dose of study drug were included in the primary efficacy and safety analyses. The main outcome was the proportion of patients with plasma HIV-1 RNA less than 50 copies per mL at week 48 as defined by US Food and Drug Administration snapshot algorithm (prespecified non-inferiority margin of 12%). This study is registered with ClinicalTrials.gov, number NCT01705574. Findings Between Nov 28, 2012, and March 12, 2014, 575 women were enrolled. 289 were randomly assigned to receive the integrase inhibitor regimen and 286 to receive the protease inhibitor based regimen. 252 (87%) women in the integrase inhibitor group had plasma HIV-1 RNA less than 50 copies per mL at week 48 compared with 231 (81%) women in the protease inhibitor group (adjusted difference 6\u00b75%; 95% CI 0\u00b74\u201312\u00b76). No participant had virological failure with resistance in the integrase inhibitor group compared with three participants ([1%]; all Met184Val/Ile) in the protease inhibitor group. 19 women in the protease inhibitor group discontinued because of adverse events compared with five in the integrase inhibitor group. Interpretation WAVES shows that clinical trials of ART regimens in global and diverse populations of treatment-naive women are possible. The findings support guidelines recommending integrase inhibitor based regimens in first-line antiretroviral therapy. Funding Gilead Sciences.", "pubmed-id": "27562742", "prism:coverDate": "2016-09-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84969972261", "dc:creator": {"author": [{"ce:given-name": "Kathleen", "preferred-name": {"ce:given-name": "Kathleen", "ce:initials": "K.", "ce:surname": "Squires", "ce:indexed-name": "Squires K."}, "@seq": "1", "ce:initials": "K.", "@_fa": "true", "affiliation": {"@id": "60015277", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015277"}, "ce:degrees": "MD", "ce:surname": "Squires", "@auid": "35394567100", "author-url": "https://api.elsevier.com/content/author/author_id/35394567100", "ce:indexed-name": "Squires K."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84969972261"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84969972261&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84969972261&origin=inward"}], "source-id": "21100369870", "pii": "S2352301816300169", "citedby-count": "75", "prism:volume": "3", "subtype": "ar", "dc:title": "Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study", "openaccess": "2", "prism:issn": "23523018", "publishercopyright": "\u00a9 2016 Elsevier Ltd", "prism:issueIdentifier": "9", "subtypeDescription": "Article", "prism:publicationName": "The Lancet HIV", "prism:pageRange": "e410-e420", "prism:endingPage": "e420", "openaccessFlag": null, "prism:doi": "10.1016/S2352-3018(16)30016-9", "prism:startingPage": "e410", "dc:identifier": "SCOPUS_ID:84969972261", "dc:publisher": "Elsevier Ltd"}, "idxterms": {"mainterm": [{"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Antiretroviral Therapy, Highly Active", "@weight": "a", "@candidate": "n"}, {"$": "Atazanavir Sulfate", "@weight": "b", "@candidate": "n"}, {"$": "Cobicistat", "@weight": "b", "@candidate": "n"}, {"$": "Double-Blind Method", "@weight": "b", "@candidate": "n"}, {"$": "Emtricitabine", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "HIV Infections", "@weight": "b", "@candidate": "n"}, {"$": "HIV Integrase Inhibitors", "@weight": "b", "@candidate": "n"}, {"$": "HIV Protease Inhibitors", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "International Cooperation", "@weight": "b", "@candidate": "n"}, {"$": "Quinolones", "@weight": "b", "@candidate": "n"}, {"$": "Ritonavir", "@weight": "b", "@candidate": "n"}, {"$": "RNA, Viral", "@weight": "b", "@candidate": "n"}, {"$": "Tenofovir", "@weight": "b", "@candidate": "n"}, {"$": "Viral Load", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": null, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Epidemiology", "@code": "2713", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Immunology", "@code": "2403", "@abbrev": "IMMU"}, {"@_fa": "true", "$": "Infectious Diseases", "@code": "2725", "@abbrev": "MEDI"}, {"@_fa": "true", "$": "Virology", "@code": "2406", "@abbrev": "IMMU"}]}, "authors": {"author": [{"ce:given-name": "Kathleen", "preferred-name": {"ce:given-name": "Kathleen", "ce:initials": "K.", "ce:surname": "Squires", "ce:indexed-name": "Squires K."}, "@seq": "1", "ce:initials": "K.", "@_fa": "true", "affiliation": {"@id": "60015277", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60015277"}, "ce:degrees": "MD", "ce:surname": "Squires", "@auid": "35394567100", "author-url": "https://api.elsevier.com/content/author/author_id/35394567100", "ce:indexed-name": "Squires K."}, {"ce:given-name": "Cissy", "preferred-name": {"ce:given-name": "Cissy", "ce:initials": "C.", "ce:surname": "Kityo", "ce:indexed-name": "Kityo C."}, "@seq": "2", "ce:initials": "C.", "@_fa": "true", "affiliation": {"@id": "60071691", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60071691"}, "ce:degrees": "MSc", "ce:surname": "Kityo", "@auid": "6602918610", "author-url": "https://api.elsevier.com/content/author/author_id/6602918610", "ce:indexed-name": "Kityo C."}, {"ce:given-name": "Sally", "preferred-name": {"ce:given-name": "Sally", "ce:initials": "S.", "ce:surname": "Hodder", "ce:indexed-name": "Hodder S."}, "@seq": "3", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60021143", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021143"}, "ce:degrees": "MD", "ce:surname": "Hodder", "@auid": "35558534100", "author-url": "https://api.elsevier.com/content/author/author_id/35558534100", "ce:indexed-name": "Hodder S."}, {"ce:given-name": "Margaret", "preferred-name": {"ce:given-name": "Margaret", "ce:initials": "M.", "ce:surname": "Johnson", "ce:indexed-name": "Johnson M."}, "@seq": "4", "ce:initials": "M.", "@_fa": "true", "affiliation": {"@id": "60032819", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032819"}, "ce:degrees": "FRCP", "ce:surname": "Johnson", "@auid": "56339842100", "author-url": "https://api.elsevier.com/content/author/author_id/56339842100", "ce:indexed-name": "Johnson M."}, {"ce:given-name": "Evgeny", "preferred-name": {"ce:given-name": "Evgeny", "ce:initials": "E.", "ce:surname": "Voronin", "ce:indexed-name": "Voronin E."}, "@seq": "5", "ce:initials": "E.", "@_fa": "true", "affiliation": {"@id": "100865118", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/100865118"}, "ce:degrees": "MD", "ce:surname": "Voronin", "@auid": "7005899830", "author-url": "https://api.elsevier.com/content/author/author_id/7005899830", "ce:indexed-name": "Voronin E."}, {"ce:given-name": "Debbie", "preferred-name": {"ce:given-name": "Debbie", "ce:initials": "D.", "ce:surname": "Hagins", "ce:indexed-name": "Hagins D."}, "@seq": "6", "ce:initials": "D.", "@_fa": "true", "affiliation": {"@id": "101795564", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/101795564"}, "ce:degrees": "MD", "ce:surname": "Hagins", "@auid": "36522862600", "author-url": "https://api.elsevier.com/content/author/author_id/36522862600", "ce:indexed-name": "Hagins D."}, {"ce:given-name": "Anchalee", "preferred-name": {"ce:given-name": "Anchalee", "ce:initials": "A.", "ce:surname": "Avihingsanon", "ce:indexed-name": "Avihingsanon A."}, "@seq": "7", "ce:initials": "A.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Avihingsanon", "@auid": "57196347321", "author-url": "https://api.elsevier.com/content/author/author_id/57196347321", "ce:indexed-name": "Avihingsanon A."}, {"ce:given-name": "Ellen", "preferred-name": {"ce:given-name": "Ellen", "ce:initials": "E.", "ce:surname": "Koenig", "ce:indexed-name": "Koenig E."}, "@seq": "8", "ce:initials": "E.", "@_fa": "true", "affiliation": {"@id": "116701788", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/116701788"}, "ce:surname": "Koenig", "@auid": "7005320371", "author-url": "https://api.elsevier.com/content/author/author_id/7005320371", "ce:indexed-name": "Koenig E."}, {"ce:given-name": "Shuping", "preferred-name": {"ce:given-name": "Shuping", "ce:initials": "S.", "ce:surname": "Jiang", "ce:indexed-name": "Jiang S."}, "@seq": "9", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60002909", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"}, "ce:degrees": "PhD", "ce:surname": "Jiang", "@auid": "57189385625", "author-url": "https://api.elsevier.com/content/author/author_id/57189385625", "ce:indexed-name": "Jiang S."}, {"ce:given-name": "Kirsten", "preferred-name": {"ce:given-name": "Kirsten", "ce:initials": "K.", "ce:surname": "White", "ce:indexed-name": "White K."}, "@seq": "10", "ce:initials": "K.", "@_fa": "true", "affiliation": {"@id": "60002909", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"}, "ce:degrees": "PhD", "ce:surname": "White", "@auid": "7402810067", "author-url": "https://api.elsevier.com/content/author/author_id/7402810067", "ce:indexed-name": "White K."}, {"ce:given-name": "Andrew", "preferred-name": {"ce:given-name": "Andrew", "ce:initials": "A.", "ce:surname": "Cheng", "ce:indexed-name": "Cheng A."}, "@seq": "11", "ce:initials": "A.", "@_fa": "true", "affiliation": {"@id": "60002909", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"}, "ce:degrees": "MD", "ce:surname": "Cheng", "@auid": "7402075263", "author-url": "https://api.elsevier.com/content/author/author_id/7402075263", "ce:indexed-name": "Cheng A."}, {"ce:given-name": "Javier", "preferred-name": {"ce:given-name": "Javier", "ce:initials": "J.", "ce:surname": "Szwarcberg", "ce:indexed-name": "Szwarcberg J."}, "@seq": "12", "ce:initials": "J.", "@_fa": "true", "affiliation": {"@id": "60002909", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"}, "ce:degrees": "MD", "ce:surname": "Szwarcberg", "@auid": "6602738587", "author-url": "https://api.elsevier.com/content/author/author_id/6602738587", "ce:indexed-name": "Szwarcberg J."}, {"ce:given-name": "Huyen", "preferred-name": {"ce:given-name": "Huyen", "ce:initials": "H.", "ce:surname": "Cao", "ce:indexed-name": "Cao H."}, "@seq": "13", "ce:initials": "H.", "@_fa": "true", "affiliation": {"@id": "60002909", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002909"}, "ce:degrees": "MD", "ce:surname": "Cao", "@auid": "56471119200", "author-url": "https://api.elsevier.com/content/author/author_id/56471119200", "ce:indexed-name": "Cao H."}]}}}